Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 596


Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials.

Sachanas S, Pangalis GA, Fink AM, Bahlo J, Fischer K, Levidou G, Kyrtsonis MC, Bartzi V, Vassilakopoulos TP, Kalpadakis C, Koulieris E, Moschogiannis M, Yiakoumis X, Tsirkinidis P, Angelopoulou MK, Eichhorst B, Hallek M.

Anticancer Res. 2019 May;39(5):2591-2598. doi: 10.21873/anticanres.13382.


Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF.

Blood. 2019 Apr 25. pii: blood.2018882555. doi: 10.1182/blood.2018882555. [Epub ahead of print]


Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S.

J Clin Oncol. 2019 Apr 17:JCO1801460. doi: 10.1200/JCO.18.01460. [Epub ahead of print]


Extracellular vesicle measurements with nanoparticle tracking analysis - An accuracy and repeatability comparison between NanoSight NS300 and ZetaView.

Bachurski D, Schuldner M, Nguyen PH, Malz A, Reiners KS, Grenzi PC, Babatz F, Schauss AC, Hansen HP, Hallek M, Pogge von Strandmann E.

J Extracell Vesicles. 2019 Apr 1;8(1):1596016. doi: 10.1080/20013078.2019.1596016. eCollection 2019.


Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.

Jebaraj BMC, Tausch E, Landau DA, Bahlo J, Robrecht S, Taylor-Weiner AN, Bloehdorn J, Scheffold A, Mertens D, Böttcher S, Kneba M, Jäger U, Zenz T, Wenger MK, Fingerle-Rowson G, Wendtner C, Fink AM, Wu CJ, Eichhorst B, Fischer K, Hallek M, Döhner H, Stilgenbauer S.

Leukemia. 2019 Mar 25. doi: 10.1038/s41375-019-0446-4. [Epub ahead of print]


The Treatment of Chronic Lymphatic Leukemia.

Tresckow JV, Eichhorst B, Bahlo J, Hallek M.

Dtsch Arztebl Int. 2019 Jan 25;116(4):41-46. doi: 10.3238/arztebl.2019.0041.


Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity.

Rossi A, Dupaty L, Aillot L, Zhang L, Gallien C, Hallek M, Odenthal M, Adriouch S, Salvetti A, Büning H.

Sci Rep. 2019 Mar 6;9(1):3631. doi: 10.1038/s41598-019-40071-1.


Bloodletting to Treat Severe Hypertriglyceridemia.

Koehler P, Bröckelmann PJ, Hallek M, Kochanek M.

Ann Intern Med. 2019 Feb 26. doi: 10.7326/L18-0706. [Epub ahead of print] No abstract available.


Feasibility and Potential Benefits of an Exercise Intervention in a Male With Down Syndrome Undergoing High-Dose Chemotherapy for Acute Lymphoblastic Leukemia: A Case Report.

Bühl L, Abel T, Wolf F, Oberste M, Bloch W, Hallek M, Elter T, Zimmer P.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419832358. doi: 10.1177/1534735419832358.


Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Al-Sawaf O, Herling CD, Holtick U, Scheid C, Cramer P, Sasse S, von Tresckow B, Tuchscherer A, Fischer K, Eichhorst B, Hallek M, Frenzel LP.

Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21. No abstract available.


Sequential therapy for patients with primary refractory acute myeloid leukemia - historical prospective analysis of the German and Israeli experience.

Ram R, Scheid C, Amit O, Chemnitz JM, Moshe Y, Hallek M, Wolf D, Avivi I, Holtick U.

Haematologica. 2019 Feb 7. pii: haematol.2018.203869. doi: 10.3324/haematol.2018.203869. [Epub ahead of print]


New roles for B cell receptor associated kinases: when the B cell is not the target.

Nguyen PH, Niesen E, Hallek M.

Leukemia. 2019 Mar;33(3):576-587. doi: 10.1038/s41375-018-0366-8. Epub 2019 Jan 30. Review.


HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?

Drößler L, Lehmann C, Töpelt K, Nierhoff D, Vehreschild JJ, Rybniker J, Hallek M, Fischer J, Stormberg V, Fätkenheuer G, Wieland U, Jung N.

Infection. 2019 Apr;47(2):293-300. doi: 10.1007/s15010-019-01271-z. Epub 2019 Jan 28.


Early Palliative Care: Pro, but Please Be Precise!

Gärtner J, Daun M, Wolf J, von Bergwelt-Baildon M, Hallek M.

Oncol Res Treat. 2019;42(1-2):11-18. doi: 10.1159/000496184. Epub 2019 Jan 26.


[Multiple myeloma].

Hallek M, Haller H.

Internist (Berl). 2019 Jan;60(1):1-2. doi: 10.1007/s00108-018-0553-8. German. No abstract available.


CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.

von Tresckow J, Cramer P, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Illmer T, Klaproth H, Estenfelder S, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst BF, Hallek M.

Leukemia. 2019 May;33(5):1161-1172. doi: 10.1038/s41375-018-0313-8. Epub 2018 Dec 19.


Management of unfit elderly patients with chronic lymphocytic leukemia.

Eichhorst B, Hallek M, Goede V.

Eur J Intern Med. 2018 Dec;58:7-13. doi: 10.1016/j.ejim.2018.02.001. Review.


On the architecture of translational research designed to control chronic lymphocytic leukemia.

Hallek M.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):1-8. doi: 10.1182/asheducation-2018.1.1. Review.


Does Exercise Have a Preventive Effect on Secondary Lymphedema in Breast Cancer Patients Following Local Treatment? - A Systematic Review.

Baumann FT, Reike A, Hallek M, Wiskemann J, Reimer V.

Breast Care (Basel). 2018 Oct;13(5):380-385. doi: 10.1159/000487428. Epub 2018 May 3. Review.


Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.

Al-Sawaf O, Bahlo J, Robrecht S, Fischer K, Herling CD, Hoechstetter M, Fink AM, von Tresckow J, Langerbeins P, Cramer P, Stilgenbauer S, Wendtner CM, Eichhorst B, Hallek M, Goede V.

Br J Haematol. 2018 Dec;183(5):727-735. doi: 10.1111/bjh.15604. Epub 2018 Nov 21.


Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van Dongen JJM.

Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19. No abstract available.


Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.

Soumerai JD, Ni A, Xing G, Huang J, Furman RR, Jones J, Sharman JP, Hallek M, Adewoye AH, Dubowy R, Dreiling L, Zelenetz AD.

Leuk Lymphoma. 2018 Nov 8:1-9. doi: 10.1080/10428194.2018.1540782. [Epub ahead of print]


Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A.

Leukemia. 2019 Apr;33(4):969-980. doi: 10.1038/s41375-018-0276-9. Epub 2018 Oct 12.


Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence.

Pasternack H, Fassunke J, Plum PS, Chon SH, Hescheler DA, Gassa A, Merkelbach-Bruse S, Bruns CJ, Perner S, Hallek M, Büttner R, Bollschweiler E, Hölscher AH, Quaas A, Zander T, Weiss J, Alakus H.

Sci Rep. 2018 Oct 8;8(1):14941. doi: 10.1038/s41598-018-33027-4.


New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.

Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G.

Leuk Lymphoma. 2019 Mar;60(3):649-657. doi: 10.1080/10428194.2018.1488253. Epub 2018 Sep 20.


[The 2017/2018 influenza season-business as usual? : A statement of medical societies].

Kochanek M, Böll B, Shimabukuro-Vornhagen A, Welte T, Wieland U, Pletz M, Hallek M, Fätkenheuer G, Salzberger B.

Internist (Berl). 2018 Oct;59(10):1122-1124. doi: 10.1007/s00108-018-0501-7. German. No abstract available.


[Individualized Treatment of Chronic Lymphocytic Leukemia (CLL)].

von Tresckow J, Hallek M, Eichhorst B.

Dtsch Med Wochenschr. 2018 Sep;143(18):1318-1324. doi: 10.1055/a-0550-2286. Epub 2018 Sep 10. German.


Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.

Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C.

Biol Blood Marrow Transplant. 2019 Mar;25(3):488-495. doi: 10.1016/j.bbmt.2018.08.029. Epub 2018 Sep 5.


Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.

Krause G, Hassenrück F, Hallek M.

Drug Des Devel Ther. 2018 Aug 21;12:2577-2590. doi: 10.2147/DDDT.S142406. eCollection 2018. Review.


Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.

Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, Engelke A, Fink AM, Fischer K, Tausch E, Seiler T, Fischer von Weikersthal L, Hebart H, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M.

Lancet Oncol. 2018 Sep;19(9):1215-1228. doi: 10.1016/S1470-2045(18)30414-5. Epub 2018 Aug 13.


Der ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis.

Bokemeyer C, Busse R, Engel J, Gebauer A, Hallek M, Heinemann V, Lüftner D, Wörmann B.

Oncol Res Treat. 2018;41 Suppl 3:2-26. doi: 10.1159/000490082. Epub 2018 Jul 26. No abstract available.



Hallek M, Bokemeyer C, Lüftner D, Weissinger F.

Oncol Res Treat. 2018;41 Suppl 3:1. doi: 10.1159/000491683. Epub 2018 Jul 26. No abstract available.


Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.

Golfmann K, Meder L, Koker M, Volz C, Borchmann S, Tharun L, Dietlein F, Malchers F, Florin A, Büttner R, Rosen N, Rodrik-Outmezguine V, Hallek M, Ullrich RT.

Oncogene. 2018 Oct;37(42):5682-5693. doi: 10.1038/s41388-018-0380-3. Epub 2018 Jul 3.


Effects of Kyusho Jitsu on Physical Activity-levels and Quality of Life in Breast Cancer Patients.

Strunk MA, Zopf EM, Steck J, Hamacher S, Hallek M, Baumann FT.

In Vivo. 2018 Jul-Aug;32(4):819-824. doi: 10.21873/invivo.11313.


Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF.

Clin Cancer Res. 2018 Sep 15;24(18):4371-4379. doi: 10.1158/1078-0432.CCR-17-3761. Epub 2018 Jun 12.


Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.

Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Klein S, Borchmann S, Wennhold K, Vlasic I, Oberbeck S, Riedel R, Florin A, Golfmann K, Schlößer HA, Odenthal M, Buettner R, Wolf J, Hallek M, Herling M, von Bergwelt-Baildon M, Reinhardt HC, Ullrich RT.

Cancer Res. 2018 Aug 1;78(15):4270-4281. doi: 10.1158/0008-5472.CAN-17-2176. Epub 2018 May 18.


Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.

Hassenrück F, Knödgen E, Göckeritz E, Midda SH, Vondey V, Neumann L, Herter S, Klein C, Hallek M, Krause G.

Biomed Res Int. 2018 Mar 19;2018:1023490. doi: 10.1155/2018/1023490. eCollection 2018.


Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG.

J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1.


Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.

Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, Stelljes M, Kröger N, Einsele H, Eder M, Hallek M, Glass B, Finke J, Ciceri F, Mohty M, Ruggeri A, Nagler A.

J Hematol Oncol. 2018 Apr 16;11(1):55. doi: 10.1186/s13045-018-0598-0.


Venetoclax after idelalisib: relevant progress for CLL.

Bosch F, Hallek M.

Blood. 2018 Apr 12;131(15):1632-1633. doi: 10.1182/blood-2018-02-826396. No abstract available.


iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ.

Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. Review.


Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial.

Schetelig J, Link CS, Stuhler G, Wagner EM, Hänel M, Kobbe G, Böttcher S, Kreuzer KA, Middeke JM, Sockel K, Teipel R, von Bonin M, Stölzel F, Kramer M, Stilgenbauer S, Hallek M, Bornhäuser M; Deutsche CLL Studiengruppe and the German Cooperative Transplant Study Group.

Br J Haematol. 2019 Mar;184(5):833-836. doi: 10.1111/bjh.15181. Epub 2018 Mar 12. No abstract available.


Chronic lymphocytic leukaemia.

Hallek M, Shanafelt TD, Eichhorst B.

Lancet. 2018 Apr 14;391(10129):1524-1537. doi: 10.1016/S0140-6736(18)30422-7. Epub 2018 Feb 21. Review.


[Which drugs in Hemato-Oncology are Unnecessary or Inappropriate for Use in the Elderly?]

Goede V, Hallek M.

Dtsch Med Wochenschr. 2018 Feb;143(4):244-252. doi: 10.1055/s-0043-106791. Epub 2018 Feb 22. German.


Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review.

Baumann FT, Reike A, Reimer V, Schumann M, Hallek M, Taaffe DR, Newton RU, Galvao DA.

Breast Cancer Res Treat. 2018 Jul;170(1):1-13. doi: 10.1007/s10549-018-4725-y. Epub 2018 Feb 22.


CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.

Cramer P, von Tresckow J, Bahlo J, Engelke A, Langerbeins P, Fink AM, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst B, Hallek M.

Future Oncol. 2018 Mar;14(6):499-513. doi: 10.2217/fon-2017-0442. Epub 2018 Feb 21.


[Internal emergency cases at the interface of outpatient and inpatient - part 2].

Kochanek M, Hallek M, Lehnert H, Schellong SM.

Internist (Berl). 2018 Mar;59(3):217. doi: 10.1007/s00108-018-0389-2. German. No abstract available.


Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.

Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, Cartolano M, Oberbeck S, Mayer P, Berg V, Thomalla D, Kutsch N, Stiefelhagen M, Cramer P, Wendtner CM, Persigehl T, Saleh A, Altmüller J, Nürnberg P, Pallasch C, Achter V, Lang U, Eichhorst B, Castiglione R, Schäfer SC, Büttner R, Kreuzer KA, Reinhardt HC, Hallek M, Frenzel LP, Peifer M.

Nat Commun. 2018 Feb 20;9(1):727. doi: 10.1038/s41467-018-03170-7.


Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M.

Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6.


[Diagnostic management of fever].

Kochanek M, Piepereit A, Böll B, Shimabukuro-Vornhagen A, Hallek M.

Internist (Berl). 2018 Mar;59(3):218-226. doi: 10.1007/s00108-018-0383-8. Review. German.


Supplemental Content

Loading ...
Support Center